



# Tenascin-C

## Heart Failure / Cancer / Auto-Immune

- Research Use Only -

### Assay Kits

【Sample Type】 H: Human M: Mouse R: Rat

Product No.	Sample Type	Product Name	Measurement Range	Measuring samples				
				Serum	Heparin-Plasma	EDTA-Plasma	Urine	Cell Culture Supernatant
27751	H	Human Tenascin-C Large (FNIII-C) Assay Kit - IBL	0.38 ~ 24 ng/mL	○	○*1	○*2		○
27767	H/M/R	Tenascin-C Large (FNIII-B) Assay Kit - IBL	0.20 ~ 12.5 ng/mL	○		○*3		○*4

\*1: more than x5 dilution is recommended.

\*2: Plasma samples collected with EDTA, Sodium citrate or NaF showed somewhat lower value.

\*3: x400 - x1600 dilution is recommended.

\*4: cross-reacts with FCS in medium.

### Antibodies

【Sample Type】 H: Human

Product No.	Sample Type	Product Name	Application	Size	Small size
10337	H	Anti-Human Tenascin-C (EGF Like Domain) (4F10TT) Mouse IgG MoAb	WB (1ug/mL), IHC (5ug/mL) * 1	100µg	10µg
10335	H	Anti-Human Tenascin-C (Domain B) (4C8MS) Mouse IgG MoAb	WB (5ug/mL), IHC (5ug/mL) *2	100µg	10µg

\*1: Can be applied to formalin fixed paraffin embedded tissue with trypsin pre-treatment.


\*2: Microwave pre-treatment is necessary.

### Structure of Tenascin-C

Tenascin-C is an extracellular matrix (ECM) glycoprotein that is composed of 210-400 kDa subunits consisting of four domains.

One subunit has a TA domain at the N-terminal end, then an epidermal growth factor-like sequence domain (EGF-like domain), a fibronectin type III (FN III) repeat domain, and a fibrinogen-like domain at the C-terminal end. There is an alternatively spliced domain in the FN III domain, and it generates some types of variants of Tenascin-C.

The subunits form a trimer by twisting at the N-terminal coiled domain and form a hexamer by a disulfide bond, in tissue.



### Distributed by:



Immuno-Biological Laboratories, Inc.  
8201 Central Ave NE, Suite P  
Minneapolis, MN 55432

Toll-Free: 888-523-1246

Email: [info@IBL-America.com](mailto:info@IBL-America.com)

Web: [www.IBL-America.com](http://www.IBL-America.com)

# Tenascin-C

27751 Human Tenascin-C Large (FNIII-C) Assay Kit – IBL  
27767 Tenascin-C Large (FNIII-B) Assay Kit - IBL

Two assay kits for measuring Tenascin-C are available. Each assay kit specifically detects FN III-B or FN III-C domain in FN III repeat and measures Tenascin-C high molecular weight variant (called as “Large”) including the subunit in which FN III-B or FN III-C domain respectively.


While low molecular weight variants of Tenascin-C are present in normal tissue, it is said that high molecular variants of Tenascin-C is expressed in various diseased tissue including cancers.

10337 Anti-Human Tenascin-C (EGF Like Domain) (4F10TT)  
Mouse IgG MoAb

This monoclonal antibody specifically recognizes EGF-like domain of Tenascin-C and it detects in all Tenascin-C isoforms and cross-react with mouse, rat, chicken and rabbit.

10335 Anti-Human Tenascin-C (Domain B) (4C8MS)  
Mouse IgG MoAb

This monoclonal antibody specifically recognizes domain B on FN III repeat of Tenascin-C and is useful for the study of organogenesis, tumor, cell injury caused by various types of stress, wound healing, regeneration and fibrosis. It cross-reacts with mouse and rat.



These are results of IHC of human breast cancer tissue (References No.6).

## References

1. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A; Study Group for Intractable Diseases by a Grant from the Ministry of Health, Labor and Welfare of Japan. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. *Circ J*. 2007 Mar;71(3):327-30.
2. Takeda A, Otani Y, Iseki H, Takeuchi H, Aikawa K, Tabuchi S, Shinozuka N, Saeki T, Okazaki Y, Koyama I. Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer. *World J Surg*. 2007 Feb;31(2):388-94.
3. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. *J Am Coll Cardiol*. 2006 Jun 6;47(11):2319-25.
4. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. *J Am Coll Cardiol*. 2006 Jun 6; 47 (11):2319-25.
5. Tanaka H, El-Karef A, Kaito M, Kinoshita N, Fujita N, Horiike S, Watanabe S, Yoshida T, Adachi Y. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. *Liver Int*. 2006 Apr; 26 (3):311-8.
6. Hasegawa M, Sudo A, Nagakura T, Hirata H, Kinoshita N, Yoshida T, Uchida A. Tenascin-C levels in pseudosynovial fluid of loose hip prostheses. *Scand J Rheumatol*. 2005 Nov-Dec; 34 (6):464-8.
7. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, Ohtsuki M, Uemura A, Kato Y, Nishikawa T, Toyozaki T, Hishida H, Yoshida T, Hiroe M. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. *J Pathol*. 2005 Mar; 205 (4):460-7.
8. Hasegawa M, Hirata H, Sudo A, Kato K, Kawase D, Kinoshita N, Yoshida T, Uchida A. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. *J Rheumatol*. 2004 Oct; 31 (10):2021-6.
9. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. *Histol Histopathol*. 2004 Apr; 19 (2):517-25.
10. Tsunoda T, Inada H, Kalembeiyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T. Involvement of large tenascin-C splice variants in breast cancer progression. *Am J Pathol*. 2003 Jun;162 (6):1857-67.
11. Sato M, Toyozaki T, Odaka K, Uehara T, Arano Y, Hasegawa H, Yoshida K, Imanaka-Yoshida K, Yoshida T, Hiroe M, Tadokoro H, Irie T, Tanada S, Komuro I. Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. *Circulation*. 2002 Sep 10;106(11):1397-402.
12. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda N, Maki T, Nishikawa T, Sakakura T, Yoshida T. Tenascin-C is a useful marker for disease activity in myocarditis. *J Pathol*. 2002 Jul;197(3):388-94.
13. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. *Lab Invest*. 2001 Jul;81(7):1015-24.
14. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. *Dev Dyn*. 2000 Jun;218(2):235-59.
15. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. *Int J Cancer*. 1997 Sep 26;73(1):10-5.
16. Yoshida T, Matsumoto E, Hanamura N, Kalembeiyi I, Katsuta K, Ishihara A, Sakakura T. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. *J Pathol*. 1997 Aug;182(4):421-8.